⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105962 | 0.56 | — | — | |
| SCHEMBL6272478 | 0.55 | — | — | |
| SCHEMBL31406261 | 0.53 | — | — | |
| SCHEMBL31406263 | 0.52 | — | — | |
| SCHEMBL52135 | 0.47 | — | — | |
| SCHEMBL320324 | 0.41 | — | — | |
| SCHEMBL18540730 | 0.41 | — | — | |
| SCHEMBL73936 | 0.37 | — | — | |
| SCHEMBL18649660 | 0.37 | — | — | |
| SCHEMBL515670 | 0.37 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| WO-2021112933-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3672976-A1 | BCL-2 INHIBITORS | Newave Pharmaceutical Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-105308036-B | The Compounds and methods for and its indication adjusted for kinases | 普莱希科公司 | 2019-06-21 | — | — | CN | disclosed |
| EP-3464295-A1 | TRICYCLIC HETEROCYLIC DERIVATIVES | Merck Patent GmbH (DE) | 2019-04-10 | — | — | EP | disclosed |
| CN-104870422-B | Amine derivative or its salt | 富士胶片富山化学株式会社 | 2019-03-15 | — | — | CN | disclosed |
| CN-105408321-B | Indoles and azole derivatives, their preparation method and the pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-08 | — | — | CN | disclosed |
| WO-2019040573-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| CN-109232358-A | Indole derivatives or its salt and its preparation method and application | 复旦大学 | 2019-01-18 | — | — | CN | disclosed |
| CN-109071565-A | Tricyclic heterocyclic derivatives | 默克专利股份公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017202748-A1 | TRICYCLIC HETEROCYLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-11-30 | — | — | WO | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |